Go to deals
Healthcare

Cellply srl has obtained a grant by the European Commission to support its R&D program

Cellply has obtained a grant by the European Commission to support its R&D program. It is the largest one among the nine Italian companies funded in the last SME Instrument call and one of the largest at EU level since the start of the SME Instrument program in 2014. This will provide the resources to complete the development of an innovative diagnostic platform.

Cellply, based in Bologna, Italy, was founded in 2013 by two engineers, Professor Roberto Guerrieri from the University of Bologna and Massimo Bocchi. It is a medtech start-up company specialized in in vitro diagnostic systems aiming at supporting personalized oncology treatments. In 2014, the company started the development of an in vitro diagnostic platform which enabled the isolation of a tiny amount of live tumor cells sampled from patients within 20,000 microwells and to analyze the action of multiple drugs in parallel by means of proprietary algorithms to predict the response of the patient to candidate drug therapies.

Oaklins' team in Italy successfully assisted Cellply along the entire fundraising process.

Service
Funding, debt advisory & ECM
Parties

Talk to the deal team

 Federico  Cappa

Federico Cappa

Partner

Milan, Italy
Oaklins Italy

Related deals

Intergrin has raised financing provided by Kartesia
Healthcare

Intergrin has raised financing provided by Kartesia

Intergrin has obtained a unitranche loan of approximately US$59 million to refinance existing debt and to further support the growth of different healthcare and well-being initiatives.

Learn more
MediCA klinika acquires G. Radavičiaus klinika
Healthcare

MediCA klinika acquires G. Radavičiaus klinika

MediCA klinika has acquired G. Radavičiaus klinika.

Learn more
Nutricare has raised US$3.1 million via an entitlement offer
Consumer & Retail | Healthcare

Nutricare has raised US$3.1 million via an entitlement offer

Nutricare Pty Ltd has raised funds to support its growth strategy.

Learn more